Institut Paoli-Calmettes clinical trial pipeline

4 trials changed in the last 30 days: 1 stopped, 1 with a notable change, 2 with minor changes only.

1. Stopped

   VEN-R DASA · DASATINIB Monotherapy Efficacy in Acute Myeloid…VEN-R DASA · DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

   Recruitment suspended

   Also in this update: Primary completion pushed from Jul 8, 2026 to Jan 2027; Study completion pushed from Oct 31, 2027 to Jan 2029

   Institut Paoli-Calmettes·Phase 2· NCT06055621· Registry history of NCT06055621 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

2. Notable

   GemSign-01 · First-Line Gemcitabine Chemotherapy in GemCore+…GemSign-01 · First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients

   Primary and study completion pushed from Nov 1, 2027 to Nov 2029

   Institut Paoli-Calmettes·Not applicable· NCT06046794· Registry history of NCT06046794 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.